Scholarlink

Purpose <p>To assess the subthreshold micropulse laser (SML) treatment in patients with acute central serous chorioretinopathy (CSC).</p> Materials and methods <p>This retrospective study included 46 eyes from 46 patients with acute CSC. Twenty-five patients were treated with SML, while 21 were observed without intervention. Outcomes evaluated included best corrected visual acuity (BCVA), outer nuclear layer thickness (ONLT), subfoveal choroidal thickness (SFCT), and subretinal fluid (SRF) height. SML was applied using a 577&#xa0;nm yellow wavelength laser.</p> Results <p>In the SML group, BCVA improved significantly from 0.33 ± 0.13 LogMAR at baseline to 0.07 ± 0.05 LogMAR at 6 months (<i>p</i> &lt; 0.001). The observation group showed improvement from 0.29 ± 0.13 LogMAR to 0.14 ± 0.16 LogMAR (<i>p</i> = 0.011). SFCT decreased significantly in the SML group (460.36 ± 67.91&#xa0;μm at baseline to 407.44 ± 60.18&#xa0;μm at 6 months, <i>p</i> = 0.013), with no significant change in the observation group. The SML group also showed a significant increase in ONLT (<i>p</i> &lt; 0.001), and complete SRF resorption was achieved in all patients, compared to 23.8% in the observation group.</p> Conclusion <p>SML treatment is a safe and effective option for managing acute CSC.</p> Trial registration number <p>2024/010.99/2/21-27.03.2024, retrospective design.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of 577 nm subthreshold laser treatment in acute central serous chorioretinopathy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月13日

查看全文
  • Güzide Akçay,
  • Hatice Selen Kanar,
  • Ulviye Kivrak,
  • Isil Uslubas,
  • Aysu Karatay Arsan

摘要

Purpose

To assess the subthreshold micropulse laser (SML) treatment in patients with acute central serous chorioretinopathy (CSC).

Materials and methods

This retrospective study included 46 eyes from 46 patients with acute CSC. Twenty-five patients were treated with SML, while 21 were observed without intervention. Outcomes evaluated included best corrected visual acuity (BCVA), outer nuclear layer thickness (ONLT), subfoveal choroidal thickness (SFCT), and subretinal fluid (SRF) height. SML was applied using a 577 nm yellow wavelength laser.

Results

In the SML group, BCVA improved significantly from 0.33 ± 0.13 LogMAR at baseline to 0.07 ± 0.05 LogMAR at 6 months (p < 0.001). The observation group showed improvement from 0.29 ± 0.13 LogMAR to 0.14 ± 0.16 LogMAR (p = 0.011). SFCT decreased significantly in the SML group (460.36 ± 67.91 μm at baseline to 407.44 ± 60.18 μm at 6 months, p = 0.013), with no significant change in the observation group. The SML group also showed a significant increase in ONLT (p < 0.001), and complete SRF resorption was achieved in all patients, compared to 23.8% in the observation group.

Conclusion

SML treatment is a safe and effective option for managing acute CSC.

Trial registration number

2024/010.99/2/21-27.03.2024, retrospective design.